Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients.
Humans
Leukemia, Myeloid, Acute
/ diagnosis
Reactive Oxygen Species
/ metabolism
Prognosis
Male
Biomarkers, Tumor
/ metabolism
Middle Aged
Female
Aldehyde Dehydrogenase 1 Family
/ metabolism
Adult
Aged
Retinal Dehydrogenase
/ metabolism
Aged, 80 and over
Young Adult
Aldehyde Dehydrogenase, Mitochondrial
/ metabolism
Aldehyde Dehydrogenase
/ metabolism
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
15
07
2024
received:
16
05
2024
accepted:
06
08
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
11
10
2024
Statut:
ppublish
Résumé
Acute myeloid leukaemia (AML) remains a major unmet medical, despite recent progress in targeted molecular therapies. One aspect of leukaemic cell resistance to chemotherapy is the development of clones with increased capacity to respond to cellular stress and the production of reactive oxygen species (ROS), thanks in particular to a high aldehyde dehydrogenases (ALDH) 1A1/2 activity. At diagnosis, ROS level and ALDH1A1/2 activity in AML patients BM are correlated with the different ELN 2022 prognostic groups and overall survival (OS). A significant lower ALDH1A1/2 activity in BM was observed in the favourable ELN2022 subgroup compared to the intermediate and adverse group (p < 0.01). In the same way, the ROS levels were significantly lower in the favourable ELN 2022 subgroup compared to the intermediate group (p < 0.0001) and adverse group (p < 0.0002). ROS
Substances chimiques
Reactive Oxygen Species
0
Biomarkers, Tumor
0
Aldehyde Dehydrogenase 1 Family
EC 1.2.1
ALDH1A1 protein, human
EC 1.2.1.36
Retinal Dehydrogenase
EC 1.2.1.36
Aldehyde Dehydrogenase, Mitochondrial
EC 1.2.1.3
ALDH2 protein, human
EC 1.2.1.3
Aldehyde Dehydrogenase
EC 1.2.1.3
Banques de données
ClinicalTrials.gov
['NCT05601726']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70011Informations de copyright
© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277‐300.
Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood. 2006;107(2):431‐434.
Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004;101(1):3‐27.
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136‐1152.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377.
Algariri ES, Mydin RBSMN, Moses EJ, et al. Knockdown of stromal interaction molecule 1 (STIM1) suppresses acute myeloblastic leukemia‐M5 cell line survival through inhibition of reactive oxygen species activities. Turk J Haematol. 2023;40(1):11‐17.
Lagunas‐Rangel FA. DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: implications for clonal evolution and disease progression. Hematol Oncol. 2023;41(1):26‐38.
Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non‐P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008;4(6):697‐720.
Dancik GM, Voutsas IF, Vlahopoulos S. Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia. Mol Biol Rep. 2022;49(4):3321‐3331.
Gasparetto M, Pei S, Minhajuddin M, et al. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. Haematologica. 2017;102(6):1054‐1065.
Fournet G, Martin G, Quash G. α,β‐acetylenic amino thiolester inhibitors of aldehyde dehydrogenases 1&3: suppressors of apoptogenic aldehyde oxidation and activators of apoptosis. Curr Med Chem. 2013;20(4):527‐533.
Canuto RA, Muzio G, Salvo RA, et al. The effect of a novel irreversible inhibitor of aldehyde dehydrogenases 1 and 3 on tumour cell growth and death. Chem Biol Interact. 2001;130–132(1–3):209‐218.
Quash G, Fournet G, Courvoisier C, et al. Aldehyde dehydrogenase inhibitors: alpha,beta‐acetylenic N‐substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture. Eur J Med Chem. 2008;43(5):906‐916.
Venton G, Pérez‐Alea M, Baier C, et al. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 2016;6(9):e469.
Farge T, Saland E, de Toni F, et al. Chemotherapy‐resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716‐735.
Hoadley KA, Yau C, Hinoue T, et al. Cell‐of‐origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291‐304.e6.
Kitson TM, Kitson KE. Studies of the esterase activity of cytosolic aldehyde dehydrogenase with resorufin acetate as substrate. Biochem J. 1997;322:701‐708.
Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487‐494.
Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target? J Natl Cancer Inst. 2004;96(8):583‐585.
Rahmati A, Goudarzi S, Sheikhi M, Siyadat P, A Ferns G, Ayatollahi H. The emerging roles of aldehyde dehydrogenase in acute myeloid leukemia and its therapeutic potential. Anti Cancer Agents Med Chem. 2023;23(3):246‐255.
Picou F, Vignon C, Debeissat C, et al. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv. 2019;3(24):4271‐4279.
Sillar JR, Germon ZP, DeIuliis GN, Dun MD. The role of reactive oxygen species in acute myeloid Leukaemia. Int J Mol Sci. 2019;20(23):6003.
Dancik GM, Varisli L, Vlahopoulos SA. The molecular context of oxidant stress response in cancer establishes ALDH1A1 as a critical target: what this means for acute myeloid leukemia. Int J Mol Sci. 2023;24(11):9372.
Yoval‐Sánchez B, Rodríguez‐Zavala JS. Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol. 2012;25(3):722‐729.